Cargando…

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study

Detalles Bibliográficos
Autores principales:	Lytvyn, Yuliya, Mufti, Asfandyar, Zaaroura, Hiba, Sachdeva, Muskaan, Lu, Justin D., Rankin, Brian D., Prajapati, Vimal H., Vender, Ronald, Yeung, Jensen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592884/ https://www.ncbi.nlm.nih.gov/pubmed/34816136 http://dx.doi.org/10.1016/j.jdin.2021.09.007

Ejemplares similares

Drug survival of guselkumab in patients with plaque psoriasis: A 2 year retrospective, multicenter study
por: Lytvyn, Yuliya, et al.
Publicado: (2021)

Dermatology: how to manage psoriasis and recognize differences in pathophysiology and presentation in patients with skin of colour
por: Lytvyn, Yuliya, et al.
Publicado: (2022)

Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class
por: Bagit, Ahmed, et al.
Publicado: (2023)

Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment
por: Sachdeva, Muskaan, et al.
Publicado: (2020)

Treatment outcomes in patients with papuloerythroderma of Ofuji: A systematic review
por: Mufti, Asfandyar, et al.
Publicado: (2021)

Efficacy and Safety of Upadacitinib for Management of Moderate-to-Severe Atopic Dermatitis: An Evidence-Based Review
por: Lytvyn, Yuliya, et al.
Publicado: (2022)

A Systematic Review Characterizing Psoriatic Arthritis Onset and Exacerbation in Patients Receiving Biologic Therapy
por: Sachdeva, Muskaan, et al.
Publicado: (2022)

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

Treatment discontinuation and rate of disease transmission in psoriasis patients receiving biologic therapy during the COVID-19 pandemic: A Canadian multicenter retrospective study
por: Georgakopoulos, Jorge R., et al.
Publicado: (2020)

Management of Alopecia Areata With Topical JAK Inhibitor Therapy: An Evidence-Based Review
por: Abduelmula, Abrahim, et al.
Publicado: (2022)

COVID-19 and wound care: A Canadian perspective
por: Mufti, Asfandyar, et al.
Publicado: (2020)

Real-world treatment outcomes with halobetasol propionate 0.01%/tazarotene 0.045% lotion in patients with mild-to-moderate plaque psoriasis: A Canadian multicenter retrospective chart review
por: Vender, Ronald, et al.
Publicado: (2022)

34223 Incidence and prognosis of COVID-19 in patients with psoriasis on apremilast: A multicenter retrospective cohort study
por: Lytvyn, Yuliya, et al.
Publicado: (2022)

Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation
por: Odnopozova, Liudmila, et al.
Publicado: (2022)

Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
por: Reddy, Vidhatha, et al.
Publicado: (2020)

Reply to: “Skin damage among health care workers managing coronavirus disease 2019”
por: Maliyar, Khalad, et al.
Publicado: (2020)

Risankizumab for psoriasis
Publicado: (2020)

Meta‐Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority
por: Witjes, Han, et al.
Publicado: (2019)

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
por: BORRONI, Riccardo G., et al.
Publicado: (2021)

Eruptive lentiginosis in resolving plaque psoriasis during treatment with risankizumab
por: Palmisano, Gerardo, et al.
Publicado: (2023)

Drugs Associated With the Development of Palmoplantar Keratoderma: A Systematic Review
por: Mirali, Sara, et al.
Publicado: (2021)

Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis
por: Khatri, Amit, et al.
Publicado: (2019)

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
por: Machado, Álvaro, et al.
Publicado: (2018)

Eruptive Seborrheic Keratoses Are Associated With a Co-Occurring Malignancy in the Majority of Reported Cases: A Systematic Review
por: Mirali, Sara, et al.
Publicado: (2021)

Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study
por: Gargiulo, Luigi, et al.
Publicado: (2022)

Risankizumab for Plaque and Guttate Psoriasis in a Patient with IgA-Related Glomerulonephritis
por: Dattola, Annunziata, et al.
Publicado: (2021)

Erythrodermic Psoriasis Managed with Risankizumab
por: Alajlan, Abdulmajeed, et al.
Publicado: (2022)

Modifications to dermatology residency education during the COVID-19 pandemic
por: Mufti, Asfandyar, et al.
Publicado: (2020)

Hereditary haemorrhagic telangiectasia: A case report
por: Mufti, Asfandyar, et al.
Publicado: (2021)

Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis
por: Gordon, K.B., et al.
Publicado: (2021)

Management of vitiligo with topical janus tyrosine kinase inhibitor therapy: An evidence-based review
por: Abduelmula, Abrahim, et al.
Publicado: (2022)

Squamous cell carcinoma arising within discoid lupus erythematous lesions: A systematic review
por: Mufti, Asfandyar, et al.
Publicado: (2020)

Risankizumab in the treatment of psoriasis – literature review
por: Banaszczyk, Katarzyna
Publicado: (2019)

Palmoplantar Psoriasis Successfully Treated With Risankizumab
por: Alajlan, Abdulmajeed M, et al.
Publicado: (2021)

Comparing the frequency of isotretinoin-induced hair loss at <0.5-mg/kg/d versus ≥0.5-mg/kg/d dosing in acne patients: A systematic review
por: Lytvyn, Yuliya, et al.
Publicado: (2022)

Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients
por: Pang, Yinuo, et al.
Publicado: (2019)

Rapidly and successful improvement of nail psoriasis with risankizumab
por: Orsini, Diego, et al.
Publicado: (2023)

A systematic review of vitiligo onset and exacerbation in patients receiving biologic therapy
por: Sachdeva, Muskaan, et al.
Publicado: (2020)

Clinical manifestations and treatment outcomes in prurigo pigmentosa (Nagashima disease): A systematic review of the literature
por: Mufti, Asfandyar, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ib78se7mr77nvor2i3dngln31e